All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
72 results for "Cancer" and "Hematologic/Blood Related Cancers"
Descartes-11 Consolidation Treatment in Patients with High Risk Multiple Myeloma who have Residual Disease after Induction Therapy
Descartes-11 Consolidation Tx in Pts with HR-MM who have Residual Disease after Induction Therapy
Protocol No
CARTESIAN-DC11B-HR-MM
Sub Category
A Phase III, Randomized Study Of Nivolumab (OPDIVO) Plus AVD Or Brentuximab Vedotin (ADCETRIS) Plus AVD In Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Nivo plus AVD or BV plus AVD in newly diagnosed advanced HL
Protocol No
SWOG-S1826-HL
Sub Category
A Randomized, Placebo-controlled, Double-blind, Phase II Trial of Nanoparticle Albumin-bound Paclitaxel (Nab-paclitaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-positive, Triple-negative Breast Cancer
Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
Protocol No
UC-16-0403-TNBC
Sub Category
PrE0905-AML: Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
Protocol No
PRECOG-PRE0905-AML
Sub Category
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy & Safety of Belantamab Mafodotin in Combination with Pomalidomide & Dex (B-Pd) versus Pomalidomide plus Bortezomib & Dex (PVd) in Participants with Relapsed/Refractory Multiple Myeloma
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Protocol No
GSK-207499-DREAMM-08
Sub Category
Daratumumab, Pomalidomide And Dexamethasone (Dpd) In Relapsed/ Refractory Light Chain Amyloidosis Patients Previously Exposed To Daratumumab
DPd in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Protocol No
WEILLCORNELL-AMY2006-DPD
Sub Category
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as Second Line Therapy for Essential Thrombocythemia
Ropeginterferon Alfa-2b (P1101) v. Anagrelide in ET Patients w/Hydroxyurea Resistance or Intolerance
Protocol No
PHARMAESSENTIA-P1101-ET
Sub Category
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Triple Combination of Pevonedistat & Venetoclax Plus Azacitidine in Adults with AML Who Are Unfit for Intensive Chemotherapy
Protocol No
TAKEDA-TAK-P2002-AML
Sub Category
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis
A Study to Evaluate the Effectiveness & Safety of CAEL-101 in Patients w/ Mayo Stage IIIb AL Amyloid
Protocol No
CAELUM-CAEL101-301
Sub Category
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis
A Study to Evaluate the Effectiveness & Safety of CAEL-101 in Patients w/ Mayo Stage IIIa AL Amyloid
Protocol No
CAELUM-CAEL101-302
Sub Category
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody, In Subjects With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma
This is a Phase 1, First-in-Human clinical trial, meaning that it is the first study where TNB-486 will be given to humans. This study is open-label, meaning that everyone on the study will receive study drug, at various doses.
The purpose of the Study is:
• To find the highest dose of the study drug that can be given without causing severe side effects.
• To identify side effects of the study drug at different doses.
• To gather early information about how well the study drug treats lymphoma
• To measure the amount of the study drug in the blood at different timepoints after study drug administration, at different doses.
• To evaluate biomarkers in your blood or other parts of your body. A biomarker is a substance in your blood or other location that may tell us something about your disease, indicate how your disease is progressing, or provide information about how effective a study drug is.
The purpose of the Study is:
• To find the highest dose of the study drug that can be given without causing severe side effects.
• To identify side effects of the study drug at different doses.
• To gather early information about how well the study drug treats lymphoma
• To measure the amount of the study drug in the blood at different timepoints after study drug administration, at different doses.
• To evaluate biomarkers in your blood or other parts of your body. A biomarker is a substance in your blood or other location that may tell us something about your disease, indicate how your disease is progressing, or provide information about how effective a study drug is.
Protocol No
TENEOBIO-TENEOTWO-TNB486-001
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Study Evaluating Safety and Efficacy of JCAR017 in Subject with rrCLL or SLL
Protocol No
JUNO-017004-TRANSCEND-CLL
Sub Category
An open-label, Phase 2a/2b study of KRT-232 in subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post PV-MF), or Post Essential Thrombocythemia MF (Post ET-MF) who have failed prior treatment with a JAK inhibitor
KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor
Protocol No
KARTOS-KRT-232-101-MF
Sub Category
A Multisite, Phase II Study of Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone (VICD) Induction in Transplant-Eligible Multiple Myeloma Patients with or without Renal Insufficiency
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple
Protocol No
IIT-DHAKAL-VICD-MM
Sub Category
A Phase 1 Study to Evaluate the Safety of BB2121 in Subjects with High Risk Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)
A Study to Evaluate the Safety of bb2121 in Subjects with High Risk NDMM (KarMMa4)
Protocol No
CELGENE-BB2121-MM-004-KARMMA4
Sub Category
Mindfulness meditation and sleep disturbance in hematopoietic cell transplant patients: inflammatory mechanisms
Mindfulness meditation and sleep disturbance in hematopoietic cell transplant patients
Protocol No
IIT-KNIGHT-SLEEPHCT
Sub Category
GILEAD-5F9009-MDS: ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk MDS
Magrolimab + Azacitidine versus Azacitidine + Placebo in Untreated MDS
Protocol No
FORTYSEVEN-5F9009-MDS
Sub Category
A Phase II Study of Split-Dose R-CHOP in Older Adults with Diffuse Large B-cell Lymphoma
Split-Dose R-CHOP for Older Adults with DLBCL
Protocol No
WON-SHAH-UW18131-SPLIT-RCHOP
Sub Category
Prospective Multicenter Study to Measure the Impact of MMprofiler on Treatment Intention in Active Multiple Myeloma Patients
PRospective Observational Multiple Myeloma Impact Study
Protocol No
SKYLINE-PROMMIS-MM
Sub Category
A Phase I Trial of Neihulizumab Monotherapy for Standard-Risk Acute GVHD
A Phase I Trial of Neihulizumab Monotherapy for Standard-Risk Acute GVHD
Protocol No
IIT-ABEDIN-NEIHULIZUMAB
Sub Category
Phase II Trial of Autologous Rapamycin-Resistant Th1/Tc1(RAPA-201) Cell Therapy of Relapsed, Refractory Multiple Myeloma
RAPA-201 T Cell Therapy for RR MM
Protocol No
RAPA-201-RRMM
Sub Category